Shilpa Medicare lands credit upgrade to IND AA-
India Ratings lifts the company one notch to a higher investment-grade category, citing improved financials. The upgrade covers **₹1,100 M** in parent bank loans.
— 7 earlier stories on Shilpa Medicare Ltd. →What's new
- India Ratings upgraded Shilpa Medicare's long-term bank facilities to IND AA- from IND A+ with stable outlook.
- Subsidiary Shilpa Pharma Lifesciences also assigned IND AA-/Stable; its NCD rating withdrawn after full repayment.
- One-notch upgrade validates improved credit profile after strong quarterly earnings and strategic deals.
Why this matters
The upgrade cuts borrowing costs and signals a sustainable turnaround. But the market likely anticipated it, given ₹89 cr net profit in Mar 2026 and partnerships in biosimilars and CDMO. The real test is whether operating performance and debt ratios hold at these levels.
What we're watching
- Whether Shilpa Medicare taps bond markets at the new rating to refinance existing debt.
- Profitability trajectory from biosimilar and CDMO ventures, which carry execution risk.
- Any further upgrades if the company maintains debt/equity below 0.25x and ROE above 3.3%.
The full read
India Ratings just moved Shilpa Medicare up a notch. The company's long-term bank facilities are now rated IND AA- from IND A+, a change that puts it in a higher investment-grade category. The upgrade covers ₹1,100 million of parent-level loans, while subsidiary Shilpa Pharma Lifesciences also received the same rating on its ₹3,750 million bank facilities. The agency's rationale: an improved credit profile. That lines up with trailing revenue growth of 32.1%, a debt/equity ratio of just 0.25x, and a March 2026 quarter that delivered ₹89 crore in net profit. But this upgrade was not out of the blue. Recent partnerships, such as the Orion biosimilar deal targeting a $4.1 billion market, a new ADC facility, and a Spanish biotech investment, had already signaled a turnaround. The rating change validates the trajectory but does not rewrite it. What matters now is whether Shilpa can keep its debt under control and maintain profit growth. That test is still ahead.
Questions answered
- What does the IND AA- rating mean for Shilpa Medicare?
- IND AA- is a high investment-grade rating, one notch below AA. It reflects a very strong capacity to meet financial commitments. The upgrade lowers perceived default risk and could reduce interest costs on future borrowings.
- Why did India Ratings upgrade the rating?
- The agency cited an improved credit profile, likely driven by trailing revenue growth of 32.1%, lower debt/equity at 0.25x, and a strong Mar 2026 quarter with ₹89 cr net profit.
- What happened to the non-convertible debentures of Shilpa Pharma Lifesciences?
- India Ratings withdrew the rating on those NCDs because they have been fully repaid. That reduces the subsidiary's debt and simplifies its capital structure.
- Was the upgrade a surprise to the market?
- Not entirely. The company's recent quarterly profit and strategic partnerships for biosimilars and CDMO had already hinted at improving fundamentals. The one-notch move was largely within expectations.
Shilpa Medicare Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on SHILPAMED →- 7 Jul 2026 · 4:30 PM IST Shilpa Medicare lands credit upgrade to IND AA-
- 10d ago Shilpa Medicare partners with Orion for Nivolumab biosimilar in Europe
- 16d ago Shilpa Medicare commissions ADC facility, targets global CDMO play
- 37d ago Shilpa Medicare buys 30% of Spanish biotech for €7M, chases a brain-cancer therapy
- 45d ago Shilpa Medicare drops Aflibercept Europe trial, delays alopecia drug